Bio-gene Technology Ltd. · ASX:BGT

Bio-gene Technology — Shareholder Meeting (November 2025)

15 slides from Bio-gene Technology's shareholder meeting presentation, Nov 19, 2025

  1. Slide 1: Annual General Meeting

    Bio-Gene Technology Limited | ASX: BGT Annual General Meeting Developing new insecticides derived from nature to achieve high impact worldwide. 19 November 2025 Presentation Tim Grogan Managing Director & CEO www.bio-gene.com.au 1

  2. Slide 2: Important Notice & Disclaimer

    Important Notice & Disclaimer This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an

  3. Slide 3: Bio-Gene Highlights

    Bio-Gene Highlights Developing two new insecticides with strong commercial validation. 01. Two New Actives Two insecticidal compounds derived from nature with novel modes of action: » Flavocide® and Qcide® are derived from a unique sub-type of eucalypt » effectiveness against some major insect pests

  4. Slide 4: Our Unique Products Derived from Nature

    Our Unique Products Derived from Nature Qcide® Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (Gypmie messmate) currently farmed in northern Australia.  14th harvest in QLD completed in 2025 Flavocide® Flavocide is based on flavesone, a naturally occurring

  5. Slide 5: Flavocide & Qcide - Multiple Market Segments

    Flavocide & Qcide - Multiple Market Segments Bio-Gene is targeting five large well-developed global markets Sectors Crop Protection Grain Storage Public Health Consumer Applications Animal Health Urban Pest Management, Vector Control for Malaria, Livestock & Pet-care Food & Fibre Stored Grain Oils,

  6. Slide 6: Flavocide & Qcide – Our Pipeline, Partners & Business Model

    Flavocide & Qcide – Our Pipeline, Partners & Business Model Bio-Gene is targeting five large well-developed global markets Active constituent Description Sectors Target uses Partners & Collaborators 1 Grain Protectant Crop protection Admixture to grain 2 Outdoor Space Spray Public health Flying inse

  7. Slide 7: Flavocide Development Path

    Flavocide Development Path Regulatory approval of a new active constituent and formulated product is a two-step process. Commercial Partner Agreements Launch Regulatory Development (market) 1. Active constituent 2. Active Manufacturing process improvements and scale-up dossier submission* constituen

  8. Slide 8: FY25 & Key Recent Achievements

    FY25 & Key Recent Achievements Envu evaluating Flavocide® for Flavocide® pilot-scale production APVMA feedback on Flavocide ® mosquito management by Rallis India Limited development plan www.bio-gene.com.au 8

  9. Slide 9: FY25 & Key Recent Achievements

    FY25 & Key Recent Achievements  Envu evaluation expanded to  Formulation development  Completed review of pipeline pest management expanded and strategic partnering priorities  Flavocide 5-batch analysis &  New patents granted and five  Opportunities to develop and GLP safety studies new paten

  10. Slide 10: FY25 & Key Recent Achievements

    FY25 & Key Recent Achievements Positive Flavocide ® efficacy results presented at leading conference www.bio-gene.com.au 10

  11. Slide 11: FY25 & Key Recent Achievements

    FY25 & Key Recent Achievements www.bio-gene.com.au 11

  12. Slide 12: FY25 & Key Recent Achievements

    FY25 & Key Recent Achievements www.bio-gene.com.au 12

  13. Slide 13: Bio-Gene’s Strategic Priorities

    Bio-Gene’s Strategic Priorities Strategy is focused on efficient development and approval of Flavocide and Qcide, with more commercial partnerships. Speed Efficient Use of Capital Particularly the pre-registration To leverage the funding from manufacturing and safety shareholders wherever possible s

  14. Slide 14: Key Forward Milestones & News Flow

    Key Forward Milestones & News Flow Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow. 01 02 03 Flavocide & Qcide development Partnering & commercial Funding & other support  Flavocide regulatory studies  New commercial partnerships 

  15. Slide 15: Questions

    Questions Contact Tim Grogan Managing Director & CEO timg@bio-gene.com.au Matthew Wright NWR Communications matt@nwrcommunications.com.au 0451 896 420 www.bio-gene.com.au 15

Bio-gene Technology — Shareholder Meeting (November 2025) on 6ix